NCT03451396 (Lifitegrast) is a Phase 4 clinical trial of Lifitegrast in Dry Eye, sponsored by Lifelong Vision Foundation.

Who is sponsoring NCT03451396?

NCT03451396 is sponsored by Lifelong Vision Foundation.

What drugs are being tested in NCT03451396?

Interventions in NCT03451396: Lifitegrast.

Is NCT03451396 still recruiting?

NCT03451396 is currently completed. Last updated 19 March 2018.

Last reviewed 2018-03-19 · How we verify

NCT03451396: Lifitegrast

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

Completed Phase 4 Last updated 19 March 2018

What this trial tests

Phase 4 trial testing Lifitegrast in Dry Eye in 30 participants. Completed in 15 March 2018.

Timeline

12 December 2016

Primary endpoint
1 February 2018

15 March 2018

Quick facts

Lead sponsor	Lifelong Vision Foundation
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	12 December 2016
Primary completion	1 February 2018
Estimated completion	15 March 2018
Sites	1 location across United States

Drugs / interventions tested

Lifitegrast (LIFITEGRAST) — full drug profile →

Conditions studied

Dry Eye — all drugs for Dry Eye →

Sponsor

Lifelong Vision Foundation

Who can join

18 and older, any sex, with Dry Eye. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.
Lu H, Zhou Q, He J, Jiang Z, et al · · 2020 · cited 570× · PMID 32968059 · DOI 10.1038/s41392-020-00315-3
Anoikis in cell fate, physiopathology, and therapeutic interventions.
Mei J, Jiang XY, Tian HX, Rong DC, et al · · 2024 · cited 30× · PMID 39286778 · DOI 10.1002/mco2.718
A Hierarchical Mechanotransduction System: From Macro to Micro.
Cao R, Tian H, Tian Y, Fu X. · · 2024 · cited 25× · PMID 38145330 · DOI 10.1002/advs.202302327
Mapping oncogenic protein interactions for precision medicine.
Sharifi Tabar M, Francis H, Yeo D, Bailey CG, et al · · 2022 · cited 20× · PMID 35113472 · DOI 10.1002/ijc.33954
Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity.
Pepose JS, Qazi MA, Devries DK. · · 2019 · cited 9× · PMID 30992657 · DOI 10.2147/opth.s196593

Verify or expand the search:

Other trials of Lifitegrast

Trials testing the same drug.

NCT07040826 — Lifitegrast Eye Drops in Healthy Subjects：Phase I Study · Phase 1 · completed
NCT04172961 — Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days · Phase 4 · unknown
NCT03866629 — The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery · completed
NCT03431272 — Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers · Phase 4 · withdrawn
NCT03686878 — Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness · Phase 4 · completed

Other recruiting trials for Dry Eye

Currently open trials in the same condition.

NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
NCT07329712 — Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy · recruiting
NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
NCT07298811 — Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment · Phase 1, PHASE2 · recruiting
NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03451396 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lifelong Vision Foundation
Last refreshed: 19 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03451396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing